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We appreciated the efforts made by Cortegiani et al. in updating the previous review (1, 2) and providing additional evidence for the clinicians facing the suspicion of fungal infection in critically 
ill, non-neutropenic patients. The group takes into account recent findings 
including 22 studies - 10 newly identified - pointing out that untargeted 
antifungal treatment did not significantly reduce or increase the all-cause 
mortality (moderate grade evidence), but might reduce the risk of proven 
invasive fungal infection (low grade evidence) and fungal colonization (risk 
significantly reduced but low quality of evidence) (1).
The issue of antifungal treatment in non-neutropenic, critically ill patients 
may or may not be analyzed by the results of a meta-analysis that included a 
20-year period, with significant dissimilarities and results of the studies con-
sidered (1, 2). For example, the first review included 12 trials and presented 
homogeneous results across all trials despite considerable heterogeneity in 
clinical and methodological characteristics (2, 3). Almost all trials of fluco-
nazole and ketoconazole separately showed a non-significant risk reduction 
with prophylaxis. When combined, fluconazole/ketoconazole reduced total 
mortality by about 25% and invasive fungal infections by about 50%. On 
the contrary, studies published in the last five years did not find any evidence 
of utility of untargeted treatment and only four studies were performed with 
echinocandins that are recommended for treatment according to the US and 
European guidelines (4, 5).
However, we believe that the scientific and the practical debate cannot easily 
be solved with a meta-analysis, which is a powerful tool but has no univer-
sal agreement on the theoretical validity and its interpretation (6). Further-
more, the main question is about its practical application, since prophylaxis, 
empiric, pre-emptive and perhaps presumptive treatment strategies may not 
immediately be changed with an untargeted antifungal treatment approach 
(1, 2, 7). While recognizing the scientific rigor and agreeing on the need for 
new and comprehensive randomized controlled trials, a practical approach 
may be more useful and applicable especially as facing the complexity of the 
debate on a daily work setting. For these reasons, we prefer to focus on treat-
ment strategies and de-escalation of antifungals, to help clinicians, to avoid 
expensive and prolonged treatment and perhaps to prevent the emergence of 
antifungal resistance.
In conclusion, we really acknowledge the efforts and the results of the 
meta-analysis of our colleagues but we believe that treatment strategies 
cannot be immediately translated into untargeted antifungal treatment 
approach. 
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